MLYS Q3 2025 Earnings — Mineralys Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

MLYSMineralys Therapeutics, Inc.

$2B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$15,000

Operating Income

-$41M

Net Income

-$37M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$29M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$600M

Total Liabilities

$24M

Stockholders' Equity

$576M

Cash & Equivalents

$218M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$15,000	$0	—
Operating Income	-$41M	-$60M	+31.6%
Net Income	-$37M	-$56M	+34.5%